Search Result

Results for "

triple

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (3) ADC Antibody (5) Adenosine Receptor (1) Adrenergic Receptor (3) Akt (4) Aldehyde Dehydrogenase (ALDH) (1) AMPK (2) Amyloid-β (1) Anaplastic lymphoma kinase (ALK) (1) Annexin A (2) Antibiotic (1) Antibody-Drug Conjugates (ADCs) (2) Apoptosis (69) Aryl Hydrocarbon Receptor (1) ATM/ATR (1) Aurora Kinase (5) Autophagy (17) Bacterial (1) Bcl-2 Family (8) Beta-secretase (2) Biochemical Assay Reagents (5) c-Fms (1) c-Myc (2) Cadherin (1) Calcium Channel (1) CaMK (1) Carbonic Anhydrase (1) Casein Kinase (2) Caspase (5) CD73 (2) CDK (13) CFTR (2) Checkpoint Kinase (Chk) (1) Chloride Channel (2) Cholinesterase (ChE) (3) ClpP (1) CXCR (1) DNA Methyltransferase (1) DNA/RNA Synthesis (3) Dopamine Receptor (2) Dopamine Transporter (8) Drug Derivative (1) DYRK (2) E1/E2/E3 Enzyme (2) EGFR (12) Endogenous Metabolite (9) Epigenetic Reader Domain (7) ERK (4) Eukaryotic Initiation Factor (eIF) (1) FAK (2) Fat Mass and Obesity-associated Protein (FTO) (1) Ferroptosis (9) FGFR (11) FLT3 (1) Fluorescent Dye (1) Free Fatty Acid Receptor (1) Fungal (1) Galectin (1) GCGR (3) GLP Receptor (3) GLUT (1) Glutaminase (2) Glutathione Peroxidase (2) GSK-3 (2) HDAC (9) Histone Methyltransferase (7) HIV (3) HSP (2) IAP (1) IGF-1R (1) Influenza Virus (2) Integrin (1) Interleukin Related (3) Isotope-Labeled Compounds (4) JAK (3) Kinesin (1) Ligands for E3 Ligase (1) Lipoxygenase (1) MDM-2/p53 (5) MicroRNA (2) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) Mitosis (1) MMP (2) MNK (1) Monoamine Transporter (2) mTOR (5) Mucin (1) NAMPT (1) Neurokinin Receptor (1) NF-κB (1) NO Synthase (1) Nuclear Hormone Receptor 4A/NR4A (1) p38 MAPK (1) PAI-1 (1) PAK (1) PARP (11) PD-1/PD-L1 (2) PDGFR (8) PERK (1) Phosphatase (4) Photosensitizer (1) PI3K (5) Polo-like Kinase (PLK) (1) PPAR (2) PROTAC Linkers (1) PROTACs (7) Protein Arginine Deiminase (2) PSMA (1) Pyruvate Kinase (1) RAD51 (1) Radionuclide-Drug Conjugates (RDCs) (1) Raf (2) RAR/RXR (1) Ras (4) Reactive Oxygen Species (ROS) (5) Reference Standards (8) Ribosomal S6 Kinase (RSK) (2) ROCK (1) SARS-CoV (1) Ser/Thr Protease (1) Serotonin Transporter (7) SHP2 (1) Sirtuin (3) Src (1) STAT (7) Survivin (1) Tau Protein (1) TNF Receptor (1) Transmembrane Glycoprotein (2) TREM receptor (1) TROP2 (5) ULK (4) VD/VDR (1) VEGFR (11) Wnt (2) YAP (1) β-catenin (1)
By Research Areas:	Cancer (205) Cardiovascular Disease (6) Endocrinology (5) Infection (7) Inflammation/Immunology (10) Metabolic Disease (10) Neurological Disease (17)
Click Chemistry:	Alkynes (5)

240

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-131067

EMI56	EGFR	Cancer
EMI56, the derivative of EMI1, displays greater potency toward mutant EGFR than EMI1. EMI56 inhibits EGFR triple mutants .

HY-101923

LYN-1604 3 Publications Verification	ULK Autophagy Apoptosis	Cancer
LYN-1604 is a potent UNC-51-like kinase 1 (ULK1) activator (EC₅₀=18.94 nM) for the research of triple negative breast cancer (TNBC) .

HY-101923B

LYN-1604 dihydrochloride 3 Publications Verification	ULK Autophagy Apoptosis	Cancer
LYN-1604 dihydrochloride is a potent UNC-51-like kinase 1 (ULK1) activator (EC₅₀=18.94 nM) for the research of triple negative breast cancer (TNBC) .

HY-161831

Antitumor agent-175	Reactive Oxygen Species (ROS)	Cancer
Antitumor agent-175 (Compound Ru2) is an antitumor agent with photocytotoxicity, demonstrating selective antitumor effects against triple-negative breast cancer (TNBC) cells .

HY-123044

Tedatioxetine Lu AA24530	5-HT Receptor Adrenergic Receptor	Neurological Disease
Tedatioxetine (Lu AA24530) acts as a serotonin and norepinephrine (NE)-preferring triple reuptake inhibitor (TRI) and 5-HT_2A, 5-HT_2C, 5-HT₃ and α_1A-adrenergic receptor antagonist .

HY-176418

BBOX-IN-1	Mitochondrial Metabolism	Cancer
BBOX-IN-1 (compound 58) is a potent BBOX inhibitor with an IC₅₀ of 0.02 μM. BBOX-IN-1 can be used in the study of triple negative breast cancer (TNBC) .

HY-P991621

EOS006215 EOS-215	TREM receptor	Cancer
EOS006215 is a humanized monoclonal antibody inhibitor targeting TREM-2. EOS006215 reprograms TREM2 ⁺ macrophages, significantly blocks their pleiotropic pro-tumoral functions and overcomes resistance. EOS215 decreases metastasis burden in orthotopic 4T1 triple negative breast cancer mice model and significantly inhibits tumor growth in anti-PD-1 resistant mice model. EOS006215 can be used to study advanced malignant solid neoplasm, such as triple negative breast cancer (TNBC) .

HY-170786

IRX5010 IRX4647F	RAR/RXR	Cancer
IRX5010 (IRX4647F), an analogue of IRX4647, is a highly selective RARγ nuclear receptor agonist. IRX5010 demonstrates inhibition of in vivo growth of EMT-6 triple negative breast cancer .

HY-101923A

LYN-1604 hydrochloride	ULK Autophagy Apoptosis	Cancer
LYN-1604 hydrochloride is a potent UNC-51-like kinase 1 (ULK1) activator (EC₅₀=18.94 nM) for the research of triple negative breast cancer (TNBC) .

HY-157210

CDK7-IN-26	CDK	Cancer
CDK7-IN-26 (compound 36) is an orally active CDK7 inhibitor (IC₅₀: 7.4 nM). CDK7-IN-26 potently inhibits the growth of triple-negative breast cancer (TNBC) cell line-derived xenograft (CDX) tumors in vivo and inhibits MDA-MB-453 cells in vitro with an IC₅₀ of 0.15 μM .

HY-124817

Col003 5 Publications Verification	HSP	Inflammation/Immunology
Col003 is a selective and potent inhibitor of Hsp47 and competitively binds to the collagen binding site on Hsp47 (IC₅₀=1.8 μM). Col003 discourages the interaction of Hsp47 with collagen and inhibits collagen secretion by destabilizing the collagen triple helix. Col003 can be used for the investigation of fibrosis

HY-162881

DS06652923	EGFR	Cancer
DS06652923 is an orally active *EGFR triple* mutation inhibitor. DS06652923 has a growth inhibition effect on Ba/F3 EGFR del19/T90M/C797S cells, with a GI₅₀** value of 9.4 nM. DS06652923 can lead to tumor regression in Ba/F3 xenograft models .

HY-176549

(Rac)-IBR120	RAD51	Cancer
(Rac)-IBR120 is the racemate of IBR120 (HY-176549A). IBR120 is a RAD51 inhibitor that has significant growth inhibition activity against MDA-MB-468 cells. (Rac)-IBR120 can be used for the research of difficult-to-treat cancers like triple negative breast cancer .

HY-131339

SP-96 1 Publications Verification	Aurora Kinase	Cancer
SP-96 is a highly potent, selective and non-ATP-competitive Aurora B (IC₅₀=0.316 nM) inhibitor and shows >2000 fold selectivity against FLT3 and KIT. SP-96 shows selective growth inhibition in NCI60 screening, incluing MDA-MD-468 (GI₅₀=107 nM). SP-96 can be used for the research of triple negative breast cancer (TNBC) .

HY-14472

Tesofensine NS-2330	Dopamine Transporter Serotonin Transporter	Metabolic Disease
Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC₅₀=6.5 nM), norepinephrine (NE;IC₅₀=1.7 nM), and serotonin (5-HT;IC₅₀=11 nM), and with potentials as an anti-obesity agent . Tesofensine is a CNS acting anti-obesity agent .

HY-130616

EGFR-IN-11	EGFR Apoptosis	Cancer
EGFR-IN-11 is a fourth-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) with an IC₅₀ of 18 nM for triple mutant EGFR ^{L858R/T790M/C797S}. EGFR-IN-11 significantly suppresses the EGFR phosphorylation, induce the apoptosis, and arrest cell cycle at G0/G1 .

HY-14472R

Tesofensine (Standard)	Dopamine Transporter Serotonin Transporter	Metabolic Disease
Tesofensine (Standard) is the analytical standard of Tesofensine. This product is intended for research and analytical applications. Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC50=6.5 nM), norepinephrine (NE;IC50=1.7 nM), and serotonin (5-HT;IC50=11 nM), and with potentials as an anti-obesity agent . Tesofensine is a CNS acting anti-obesity agent .

HY-P99843

Datopotamab	TROP2 ADC Antibody	Cancer
Datopotamab (CDP7657) is a humanized anti trophoblast cell surface antigen 2 (TROP2) antibody. Datopotamab can generate antibody drug conjugates (ADC) (HY-141598) with DNA topoisomerase I inhibitor Deruxtecan (HY-13631E). Datopotamab can be used in the study of triple negative breast cancer and non-small cell lung cancer .

HY-103157

PD146176 5 Publications Verification NSC168807	Autophagy Ferroptosis	Cardiovascular Disease
PD146176 (NSC168807), a 15-Lipoxygenase (15-LO) inhibitor, inhibits rabbit reticulocyte 15-LO (K_i=197 nM, IC₅₀=0.54 μM). PD146176 reverses cognitive impairment, brain amyloidosis, and tau pathology by stimulating autophagy in aged triple transgenic mice .

HY-103157R

PD146176 (Standard) NSC168807 (Standard)	Reference Standards Autophagy Ferroptosis	Cardiovascular Disease
PD146176 (Standard) is the analytical standard of PD146176. This product is intended for research and analytical applications. PD146176 (NSC168807), a 15-Lipoxygenase (15-LO) inhibitor, inhibits rabbit reticulocyte 15-LO (Ki=197 nM, IC50=0.54 μM). PD146176 reverses cognitive impairment, brain amyloidosis, and tau pathology by stimulating autophagy in aged triple transgenic mice .

HY-P991620

JS006	Transmembrane Glycoprotein	Cancer
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) .

HY-147373

DA-PROTAC	PROTACs Ligands for E3 Ligase	Cancer
DA-PROTAC is a potent PROTAC degrader of copper ion-transport proteins Atox1 and CCS. DA-PROTAC can bind both Atox1 and CCS proteins, and the complex can be bound to E3 ligase, leading to increased levels of ubiquitination of Atox1 and CCS and degradation of Atox1 and CCS proteins via the proteasome pathway. DA-PROTAC can be used for triple negative breast cancer research .

HY-P991572

MM-151	EGFR	Cancer
MM-151 is a humanized IgG1 monoclonal antibody targeting EGFR. MM-151 binds multiple regions of the EGFR extracellular domain (ECD) and reduces its mutations in circulating cell-free tumor DNA with EGFR resistance. MM-151 significantly inhibits EGFR signaling and cell growth. MM-151 can be used for drug-resistant cancers research, such as colorectal, non-small cell lung and triple negative breast cancer .

HY-113593

GSK1360707	Biochemical Assay Reagents	Others
GSK1360707 is a triple uptake inhibitor targeting nitrogen and olefin substitution reactions.

HY-114979

Pyoluteorin	Antibiotic Fungal Apoptosis	Infection Cancer
Pyoluteorin is an antibiotic that inhibits Oomycete fungi, including the plant pathogen Pythium ultimum, and suppresses plant diseases caused by this fungus . Pyoluteorin induces human triple-negative breast cancer MDA-MB-231 cells apoptosis in vitro. Pyoluteorin can be used for the research of human triple-negative breast cancer .

HY-12015

Iniparib 5+ Cited Publications BSI-201; NSC-746045; IND-71677	PARP Influenza Virus	Cancer
Iniparib (BSI-201) is an irreversible inhibitor of PARP1, used in the research of triple negative breast cancer.

HY-12850

Dasotraline SEP 225289	Dopamine Transporter Serotonin Transporter	Neurological Disease
Dasotraline is a triple reuptake inhibitor that blocks dopamine, norepinephrine, and serotonin transporters with IC₅₀ values of 4, 6, and 11 nM, respectively.

HY-142908

Maximiscin	Endogenous Metabolite	Cancer
Maximiscin, a fungal metabolite, induces DNA damage and shows selective cytotoxic activity against a subtype of triple-negative breast cancer.

HY-139832

MCX 28	PI3K mTOR	Cancer
MCX 28, a triple PI3K/mTOR/PIM inhibitor, displays low nanomolar activity.

HY-139742

ADTL-SA1215 1 Publications Verification	Sirtuin	Cancer
ADTL-SA1215 is a first-in-class specific small-molecule activator of SIRT3 that modulates autophagy in triple negative breast cancer.

HY-12850A

Dasotraline hydrochloride SEP-225289 hydrochloride	Serotonin Transporter Dopamine Transporter	Neurological Disease
Dasotraline hydrochloride (SEP-225289 hydrochloride) is a triple reuptake inhibitor that blocks dopamine, norepinephrine, and serotonin transporters with IC₅₀ values of 4, 6, and 11 nM, respectively.

HY-U00096

Ansofaxine hydrochloride LY03005; LPM570065	5-HT Receptor Dopamine Receptor	Neurological Disease Inflammation/Immunology
Ansofaxine hydrochloride (LY03005; LPM570065) is a triple reuptake inhibitor; inhibits serotonin, dopamine and norepinephrine reuptake with IC₅₀ values of 723, 491 and 763 nM, respectively.

HY-125465

SLLN-15	Autophagy	Cancer
SLLN-15 is an oral active, selective and potent enhancer of autophagy that activates cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC) .

HY-132883

EGFR/CSC-IN-1	EGFR	Cancer
EGFR/CSC-IN-1 is a potential EGFR (IC₅₀ 10.52 nM) and cancer stem cell (CSC) dual inhibitor for triple-negative breast cancer research.

HY-139830

Dyrk1A-IN-1	DYRK	Neurological Disease
Dyrk1A-IN-1 is a triple inhibitor of Dyrk1A kinase activity (IC₅₀ = 119 nM) and the aggregation of tau and α-syn oligomers.

HY-138123

Fmoc-Glu(OtBu)-OSu	Biochemical Assay Reagents	Others
Fmoc-Glu(OtBu)-OSu is used for synthesizing N3S chelators and double branched and triple branched carboxyl terminated polyethylene glycol reagents .

HY-131066

EMI48	EGFR	Cancer
EMI48, the derivative of EMI1, displays greater potency toward mutant EGFR than EMI1. EMI48 inhibits EGFR triple mutants .

HY-163381

Antiproliferative agent-48	Others	Cancer
Antiproliferative agent-48 (compound PC-A1) shows selective antiproliferative activity against triple-negative breast cancer (TNBC) cells .

HY-152536

iNOS inhibitor-10	NO Synthase	Cancer
iNOS inhibitor-10 is an iNOS inhibitor (IC₅₀: 65 nM). iNOS inhibitor-10 has antiproliferative effect against triple negative breast cancer cells .

HY-119653

AZ9482	PARP	Cancer
AZ9482 is a triple PARP1/2/6 inhibitor, with IC₅₀ values of 1 nM, 1 nM and 640 nM for PARP1, PARP2 and PARP6, respectively .

HY-164789

Sacituzumab tirumotecan SKB264; MK-2870	Antibody-Drug Conjugates (ADCs) TROP2	Cancer
Sacituzumab tirumotecan (SKB264/MK-2870) is a TROP2 ADC. Sacituzumab tirumotecan can be used for the research of triple-negative breast cancer (TNBC) .

HY-19634

YK-3-237 1 Publications Verification	Sirtuin	Cancer
YK-3-237, a SIRT1 activator, targets mutant p53. YK-3-237 inhibits the proliferation of triple-negative breast cancer cells .

HY-150757

Autophagy-IN-2	Autophagy Apoptosis	Cancer
Autophagy-IN-2 (Compound 7h) is an autophagic flux inhibitor. Autophagy-IN-2 induces cancer cell apoptosis and can be used for triple-negative breast cancer research .

HY-Y0519

Pyrimidine	Endogenous Metabolite	Neurological Disease Cancer
Pyrimidine is a nitrogen-containing heterocyclic compound and endogenous metabolite. Pyrimidine derivatives can be used in pancreatic cancer, triple-negative breast cancer, colon carcinoma and neuron research .

HY-12015R

Iniparib (Standard)	PARP Influenza Virus	Cancer
Iniparib (Standard) is the analytical standard of Iniparib. This product is intended for research and analytical applications. Iniparib (BSI-201) is an irreversible inhibitor of PARP1, used in the research of triple negative breast cancer.

HY-N7215

Jatrophone	β-catenin Wnt	Cancer
Jatrophone is a diterpenoid with anticancer activity isolated from Jatropha isabelli. Jatrophone interferes with the Wnt/β-catenin pathway to inhibit the proliferation and epithelial-mesenchymal transition (EMT) of triple-negative breast cancer cells.

HY-156077

anti-TNBC agent-2	Apoptosis DNA/RNA Synthesis	Cancer
anti-TNBC agent-2 (3j) an anti-Triple negative breast cancer (TNBC) purine derivative. anti-TNBC agent-2 induces MDA-MB-231 cells apoptosis, and inhibits its migration and angiogenesis. anti-TNBC agent-2 inhibits tumor growth and metastasis and reduces the expression of Ki67 and CD31 protein in TNBC xenograft models. anti-TNBC agent-2 can be used for Triple negative breast cancer (TNBC) research .

HY-132885

PARP/EZH2-IN-1	PARP Histone Methyltransferase	Cancer
PARP/EZH2-IN-1 is a first-in-class dual PARP (IC₅₀ 6.87 nM) and EZH2 (IC₅₀ 36.51 nM) inhibitor for triple-negative breast cancer with wild-type BRCA.

HY-149259

FAK-IN-9	FAK	Cancer
FAK-IN-9 (Compound 8f) is a potent and orally active FAK inhibitor with an IC₅₀ of 27.44 nM. FAK-IN-9 induces triple-negative breast cancer (TNBC) cell apoptosis .

HY-174836

ZINC000081009201	PARP	Cancer
ZINC000081009201 is a potent poly(ADP-ribose) polymerase 1 (PARP1) inhibitor with an IC₅₀ value of 1.4767 μM. ZINC000081009201 is promising for research of triple-negative breast cancer (TNBC) .

Cat. No.	Product Name

HY-L074

Anti-Breast Cancer Compound Library

2,624 compounds

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).

Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.

MCE supplies a unique collection of 2,624 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Cat. No.	Product Name	Type

HY-169130

Lyso BD-1	Fluorescent Dyes/Probes
Lyso BD-1, preferentially colocalized in lysosomes and lipid droplets, displays excellent photocytotoxicity (5.57 μM) on triple negative breast cancer cells under white light. Lyso BD-1 displays emission band at 560nm .

Cat. No.	Product Name	Target	Research Area

HY-P3506

Retatrutide 2 Publications Verification LY3437943	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .

HY-P3506A

Retatrutide TFA 2 Publications Verification LY3437943 TFA	GLP Receptor GCGR	Metabolic Disease
Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .

HY-P6172

GCO-(GPO)10-GCOG	Bacterial	Infection
GCO-(GPO)10-GCOG is a GPO repeat-containing peptide with a single collagen triple helix structure similar to collagen. The cross-linked triple helix GCO-(GPO)10-GCOG can form a collagen-related peptide (CRP) mimetic that tightly binds to the Yersinia adhesin YadA. YadA mediates the adhesion of the human enteric pathogen Yersinia enterocolitica to collagen and other extracellular matrix components, potentially interfering with host processes mediated by endogenous collagen-binding proteins in vivo. GCO-(GPO)10-GCOG can be used to study YadA-associated infections .

HY-P10853

Bacilotetrin C analogue	Autophagy	Cancer
Bacilotetrin C analogue is cytotoxic to triple-negative breast cancer cell line MDA-MB-231 with an IC₅₀ of 0.48 μM. Bacilotetrin C analogue can induce tumor cell autophagy and has anti-tumor activity .

HY-P5297

DOTA-CXCR4-L	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with [68Ga]/[177Lu] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P3506B

Retatrutide acetate LY3437943 acetate	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) acetate is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity .

HY-P10947

MACTIDE-V	Epigenetic Reader Domain YAP	Cancer
MACTIDE-V is an orally active and selective peptide-drug conjugate targeting CD206. MACTIDE-V delivers Verteporfin (HY-B0146) to CD206 ⁺ tumor-associated macrophages (TAM) to inhibit the YAP/TAZ signaling pathway, prompting YAP exclusion from the nucleus, inducing TAM polarization toward an anti-tumoral phenotype with enhanced phagocytosis and antigen presentation, and boosting T cell infiltration and NK cell activity. MACTIDE-V suppresses primary tumor growth and lung metastasis in triple-negative breast cancer (TNBC) mouse models .

Cat. No.	Product Name	Target	Research Area

HY-P99843

Datopotamab	TROP2 ADC Antibody	Cancer
Datopotamab (CDP7657) is a humanized anti trophoblast cell surface antigen 2 (TROP2) antibody. Datopotamab can generate antibody drug conjugates (ADC) (HY-141598) with DNA topoisomerase I inhibitor Deruxtecan (HY-13631E). Datopotamab can be used in the study of triple negative breast cancer and non-small cell lung cancer .

HY-P99045

Sacituzumab	ADC Antibody TROP2	Cancer
Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .

HY-P991621

EOS006215 EOS-215	TREM receptor	Cancer
EOS006215 is a humanized monoclonal antibody inhibitor targeting TREM-2. EOS006215 reprograms TREM2 ⁺ macrophages, significantly blocks their pleiotropic pro-tumoral functions and overcomes resistance. EOS215 decreases metastasis burden in orthotopic 4T1 triple negative breast cancer mice model and significantly inhibits tumor growth in anti-PD-1 resistant mice model. EOS006215 can be used to study advanced malignant solid neoplasm, such as triple negative breast cancer (TNBC) .

HY-P991620

JS006	Transmembrane Glycoprotein	Cancer
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) .

HY-P991572

MM-151	EGFR	Cancer
MM-151 is a humanized IgG1 monoclonal antibody targeting EGFR. MM-151 binds multiple regions of the EGFR extracellular domain (ECD) and reduces its mutations in circulating cell-free tumor DNA with EGFR resistance. MM-151 significantly inhibits EGFR signaling and cell growth. MM-151 can be used for drug-resistant cancers research, such as colorectal, non-small cell lung and triple negative breast cancer .

HY-P991319

TAB-004	Mucin	Cancer
TAB-004 is a human monoclonal antibody (mAb) targeting MUC1. TAB-004 specifically recognizes tMUC1 in all major subtypes of breast cancer without affecting normal breast epithelial cells. TAB-004 can be used in triple-negative breast cancer (TNBC) research .

HY-P991292

AB-3A4	ADC Antibody	Cancer
AB-3A4 is a human IgG1 monoclonal antibody (mAb) targeting KAAG1. AB-3A4 can be used in the study of ovarian cancer, triple-negative breast cancer, and prostate cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P990552A

huATN-658 MNPR-101	Integrin	Cancer
huATN-658 (MNPR-101) is a humanized monoclonal antibody inhibitor targeting urokinase-type plasminogen activator receptor (uPAR). huATN-658 blocks the interaction between uPAR and integrins, inhibiting the proliferation, invasion and migration of tumor cells. huATN-658 is promising for research of breast cancer (especially triple-negative breast cancer) .

HY-P991372

Anti-TROP2 Antibody RN927C antibody	TROP2	Cancer
Anti-TROP2 Antibody (RN927C antibody) is a human monoclonal antibody (mAb) targeting TROP2. Anti-TROP2 Antibody has an inhibitory effect on multiple tumor cell lines in vitro. Anti-TROP2 Antibody has anti-tumor activity in mouse pancreatic PDX, ovarian PDX, lung LG0476 PDX, and triple-negative breast cancer (TNB) PDX models .

HY-P99045A

Sacituzumab (powder)	ADC Antibody TROP2	Cancer
Sacituzumab (powder) is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab (powder) demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab (powder) can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .

HY-141600

Aprutumab ixadotin BAY 1187982	Antibody-Drug Conjugates (ADCs) FGFR Microtubule/Tubulin Apoptosis	Cancer
Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) to target FGFR2 and the first to use Auristatin-based payload. Aprutumab ixadotin contains a fully human anti-FGFR2 monoclonal antibody (Aprutumab) (HY-P99007) conjugated by lysine side chains to a non-cleavable linker and via this an innovative Auristatin W derivative. Aprutumab ixadotin can be used for the study of advanced solid tumors, such as FGFR2-positive gastric cancer and triple-negative breast cancer .

HY-P991356

FAZ-053 LAE-005	PD-1/PD-L1	Cancer
FAZ-053 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. FAZ-053 inhibits the interaction of PD-L1 with PD-1 and B7-1 on monocytes, dendritic cells, and B cells. FAZ-053 enhances interleukin 2 production. FAZ-053 can be used in advanced alveolar soft tissue sarcoma (ASPS), chordoma, and triple-negative breast cancer research .

HY-P990211

Anti-Mouse IL-6R Antibody (15A7)	Interleukin Related	Inflammation/Immunology Cancer
Anti-Mouse IL-6R Antibody (15A7) is a rat-derived anti-mouse IL-6R IgG2b κ type antibody inhibitor. Anti-Mouse IL-6R Antibody (15A7) blocks IL-6 binding to IL-6Rα and inhibits both IL-6 classic and trans-signaling. Anti-Mouse IL-6R Antibody (15A7) can be used for the researches of cancer and inflammation, such as triple-negative breast cancer .

HY-P99682

Ladiratuzumab hLIV22	ADC Antibody	Cancer
Ladiratuzumab (hLIV22) is a humanized monoclonal antibody against zinc transporter LIV-1/ZIP6. Ladiratuzumab is conjugated to MMAE (HY-15162) via a cleavable dipeptide linker to synthesize an antibody-drug conjugate (ADC) Ladiratuzumab vedotin (HY-P99683). Ladiratuzumab vedotin selectively targets LIV-1 protein overexpressed on the surface of tumor cells, enters cells through antibody-mediated receptor endocytosis, releases MMAE to inhibit microtubule polymerization, and kills adjacent tumor cells with a bystander effect. Ladiratuzumab can be used in the study of solid tumors such as metastatic triple-negative breast cancer (mTNBC) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-Y0519

Pyrimidine	Structural Classification Natural Products Microorganisms Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Pyrimidine is a nitrogen-containing heterocyclic compound and endogenous metabolite. Pyrimidine derivatives can be used in pancreatic cancer, triple-negative breast cancer, colon carcinoma and neuron research .

HY-N0770

Isoliensinine	Alkaloids Structural Classification Monophenols Classification of Application Fields Source classification Phenols Nelumbo nucifera Gaertn. Plants Isoquinoline Alkaloids Nymphaeaceae Inflammation/Immunology Disease Research Fields	Apoptosis
Isoliensinine is a bisbenzylisoquinoline alkaloid extracted from the seed embryo of Nelumbo nucifera, with anti-oxidant and anti-inflammatory and anti-cancer activities. Isoliensinine induces apoptosis in triple-negative human breast cancer cells .

HY-N6007

Chrysosplenol D	Infection Flavonols Structural Classification Flavonoids other families Classification of Application Fields Source classification Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields	Apoptosis
Chrysosplenol D is a methoxy flavonoid that induces ERK1/2-mediated apoptosis in triple negative human breast cancer cells. Chrysosplenol D also exhibits anti-inflammatory and moderate antitrypanosomal activities .

HY-N0331

Ziyuglycoside I	Triterpenes Structural Classification Classification of Application Fields Sanguisorba officinalis Linn. Terpenoids Source classification Rosaceae Plants Disease Research Fields Cancer	MDM-2/p53 Apoptosis
Ziyuglycoside I isolated from S. officinalis root, has anti-wrinkle activity, and increases the expression of type I collagen. Ziyuglycoside I could be used as an active ingredient for cosmetics . Ziyuglycoside I triggers cell cycle arrest and apoptosis mediated by p53, it can be a potential agent candidate for treating triple-negative breast cancer (TNBC) .

HY-113593

GSK1360707	Oleaceae Source classification Forsythia suspensa (Thunb.) Vahl Plants	Biochemical Assay Reagents
GSK1360707 is a triple uptake inhibitor targeting nitrogen and olefin substitution reactions.

HY-142908

Maximiscin	Structural Classification Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite
Maximiscin, a fungal metabolite, induces DNA damage and shows selective cytotoxic activity against a subtype of triple-negative breast cancer.

HY-N7215

Jatrophone	Structural Classification Microorganisms Terpenoids Source classification Diterpenoids	β-catenin Wnt
Jatrophone is a diterpenoid with anticancer activity isolated from Jatropha isabelli. Jatrophone interferes with the Wnt/β-catenin pathway to inhibit the proliferation and epithelial-mesenchymal transition (EMT) of triple-negative breast cancer cells.

HY-118618

Eucannabinolide Hiyodorilactone A; Schkuhrin I	Structural Classification Terpenoids Sesquiterpenes Source classification Plants Compositae Guilandina minax (Hance) G. P. Lewis	STAT
Eucannabinolide is a STAT3 inhibitor. Eucannabinolide suppresses STAT3 activation at tyrosine 705, inhibiteds its translocation to nucleus, and decreases its DNA binding capacity. Eucannabinolide can be used for triple negative breast cancer (TNBC) diseases research .

HY-Y0519R

Pyrimidine (Standard)	Structural Classification Natural Products Microorganisms Source classification Endogenous metabolite	Reference Standards Endogenous Metabolite
Pyrimidine (Standard) is the analytical standard of Pyrimidine. This product is intended for research and analytical applications. Pyrimidine is a nitrogen-containing heterocyclic compound and endogenous metabolite. Pyrimidine derivatives can be used in pancreatic cancer, triple-negative breast cancer, colon carcinoma and neuron research .

HY-N0331R

Ziyuglycoside I (Standard)	Triterpenes Structural Classification Sanguisorba officinalis Linn. Terpenoids Source classification Rosaceae Plants	Reference Standards MDM-2/p53 Apoptosis
Ziyuglycoside I (Standard) is the analytical standard of Ziyuglycoside I. This product is intended for research and analytical applications. Ziyuglycoside I isolated from S. officinalis root, has anti-wrinkle activity, and increases the expression of type I collagen. Ziyuglycoside I could be used as an active ingredient for cosmetics . Ziyuglycoside I triggers cell cycle arrest and apoptosis mediated by p53, it can be a potential agent candidate for treating triple-negative breast cancer (TNBC) .

HY-108692

Enterolactone	Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Source classification Lignans Phenylpropanoids Endogenous metabolite Disease Research Fields Cancer	Apoptosis Endogenous Metabolite
Enterolactone is a bioactive phenolic metabolite known as a mammalian lignan derived from dietary lignans. Enterolactone has estrogenic properties and anti-breast cancer activity . Enterolactone is a radiosensitizer for human breast cancer cell lines through impaired DNA repair and increased apoptosis .

HY-108692R

Enterolactone (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Source classification Lignans Phenylpropanoids Endogenous metabolite	Reference Standards Apoptosis Endogenous Metabolite
Enterolactone (Standard) is the analytical standard of Enterolactone. This product is intended for research and analytical applications. Enterolactone is a bioactive phenolic metabolite known as a mammalian lignan derived from dietary lignans. Enterolactone has estrogenic properties and anti-breast cancer activity . Enterolactone is a radiosensitizer for human breast cancer cell lines through impaired DNA repair and increased apoptosis .

HY-N0858

Gomisin G 1 Publications Verification	Infection Structural Classification Classification of Application Fields Source classification Lignans Phenylpropanoids Plants Schisandraceae Schisandra chinensis (Turcz.) Baill. Disease Research Fields	HIV
Gomisin G is a lignin from S. chinesis with anti-HIV (EC₅₀ = 0.006 μg/mL), anti-liver cancer and anti-inflammatory activities. Gomisin G has an AKT-cyclin D1 dependent mechanism against triple-negative breast cancer (TNBC) cells through suppressing phosphorylation rather than inducing apoptosis. Gomisin G can inhibit AKT phosphorylation. Gomisin G can cause cell cycle arrest in the G1 phase. Gomisin G can be studied in research for diseases such as HIV, breast and liver cancers .

HY-40136

cis-4-Hydroxy-L-proline	Structural Classification Microorganisms Classification of Application Fields Santalum album Linn. Ketones, Aldehydes, Acids Source classification Metabolic Disease Plants Endogenous metabolite Disease Research Fields Santalaceae	Endogenous Metabolite
cis-4-Hydroxy-L-proline is an orally active proline analog and collagen production inhibitor. cis-4-Hydroxy-L-proline inhibits cell growth by preventing the deposition of triple helical collagen on the cell layer. cis-4-Hydroxy-L-proline inhibits N-nitrosomethylurea-induced breast tumor growth. cis-4-Hydroxy-L-proline improves lung compliance and reduces prostate weight. cis-4-Hydroxy-L-proline can be used in the study of hypoxic pulmonary hypertension .

HY-N0858R

Gomisin G (Standard)	Structural Classification Source classification Lignans Phenylpropanoids Plants Schisandraceae Schisandra chinensis (Turcz.) Baill.	Reference Standards HIV
Gomisin G (Standard) is the analytical standard of Gomisin G. This product is intended for research and analytical applications. Gomisin G is a lignin from S. chinesis with anti-HIV (EC₅₀ = 0.006 μg/mL), anti-liver cancer and anti-inflammatory activities. Gomisin G has an AKT-cyclin D1 dependent mechanism against triple-negative breast cancer (TNBC) cells through suppressing phosphorylation rather than inducing apoptosis. Gomisin G can inhibit AKT phosphorylation. Gomisin G can cause cell cycle arrest in the G1 phase. Gomisin G can be studied in research for diseases such as HIV, breast and liver cancers .

HY-40136R

cis-4-Hydroxy-L-proline (Standard)	Structural Classification Microorganisms Santalum album Linn. Ketones, Aldehydes, Acids Source classification Plants Endogenous metabolite Santalaceae	Reference Standards Endogenous Metabolite
cis-4-Hydroxy-L-proline (Standard) is the analytical standard of cis-4-Hydroxy-L-proline (HY-40136). This product is intended for research and analytical applications. cis-4-Hydroxy-L-proline is an orally active proline analog and collagen production inhibitor. cis-4-Hydroxy-L-proline inhibits cell growth by preventing the deposition of triple helical collagen on the cell layer. cis-4-Hydroxy-L-proline inhibits N-nitrosomethylurea-induced breast tumor growth. cis-4-Hydroxy-L-proline improves lung compliance and reduces prostate weight. cis-4-Hydroxy-L-proline can be used in the study of hypoxic pulmonary hypertension .

Species:	Human (1) Rat (1)
Tag:	His (2)
Source:	HEK293 (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P70092

	CTHRC1 Protein, Human (HEK293, His) 3 Publications Verification rHuCollagen triple helix repeat-containing protein 1/CTHRC1, His; Collagen triple helix repeat-containing protein 1; Protein NMTC1; CTHRC1	Human	HEK293
	CTHRC1 Protein, Human (HEK293, His) is a negative regulator of collagen matrix deposition. CTHRC1, a secreted 28-kDa protein, is a glycosylated protein with a signal sequence.

HY-P76299

	CTHRC1 Protein, Rat (HEK293, His) Collagen triple helix repeat-containing protein 1; Protein NMTC1; CTHRC1	Rat	HEK293
	CTHRC1, with predicted Wnt-protein and frizzled binding activity, influences cell migration. Located in the extracellular matrix, this protein, implicated in Barrett's esophagus, exhibits biased expression in lung (RPKM 46.1) and muscle (RPKM 36.6), suggesting its role in diverse physiological processes across tissues. CTHRC1 Protein, Rat (HEK293, His) is the recombinant rat-derived CTHRC1 protein, expressed by HEK293 , with C-His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-50904S2

Nintedanib-d8
Nintedanib-d₈ is deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-50904S1

Nintedanib-13C,d3
Nintedanib- ¹³C,d₃ is the ¹³C- and deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-40136S

cis-4-Hydroxy-L-proline-d3

cis-4-Hydroxy-L-proline-d₃ is the deuterium labeled cis-4-Hydroxy-L-proline (HY-40136). cis-4-Hydroxy-L-proline is an orally active proline analog and collagen production inhibitor. cis-4-Hydroxy-L-proline inhibits cell growth by preventing the deposition of triple helical collagen on the cell layer. cis-4-Hydroxy-L-proline inhibits N-nitrosomethylurea-induced breast tumor growth. cis-4-Hydroxy-L-proline improves lung compliance and reduces prostate weight. cis-4-Hydroxy-L-proline can be used in the study of hypoxic pulmonary hypertension .

HY-50904S

Nintedanib-d3
Nintedanib-d₃ is the deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-145603S

Vanzacaftor-d4

Vanzacaftor-d₄ (VX-121-d₄) is the deuterium labeled Vanzacaftor (HY-145603). Vanzacaftor is an orally active noval corrector of Cystic fibrosis transmembrane conductance regulator (CFTR). Vanzacaftor improves processing and trafficking of CFTR protein as well as increases chloride transport in triple combined with Tezacaftor (HY-15448) and Deutivacaftor. Vanzacaftor-Tezacaftor-Deutivacaftor is safe and well tolerated, improving lung function, respiratory symptoms, and CFTR function with cystic fibrosis, which is promising for research in the field of cystic fibrosis diseases .

Cat. No.	Product Name		Classification

HY-145749

PARPYnD		Alkynes
PARPYnD is a PARP enzyme photoaffinity probe (AfBP) based on the triple PARP1/2/6 inhibitor AZ9482 (HY-119653), which induces breast cancer Formation of multipolar spindles (MPS) in cells. PARPYnD inhibits PAPR wih IC₅₀ of 38 nM (PARP1), 6 nM (PARP2), 230 nM (PARP6), respectively. PARPYnD enriches recombinant PARP6 incorporated into cell lysates and inhibits PARP6 in cell-free assays, but it does not label PARP6 in intact cells .

HY-135699

TD52 2 Publications Verification		Alkynes
TD52, an Erlotinib (HY-50896) derivative, is an orally active, potent cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibitor. TD52 mediates the apoptotic effect in triple-negative breast cancer (TNBC) cells via regulating the CIP2A/PP2A/p-Akt signalling pathway. TD52 indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter. TD52 has less p-EGFR inhibition and has potent anti-cancer activity . TD52 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-135699A

TD52 dihydrochloride 2 Publications Verification		Alkynes
TD52 dihydrochloride, an Erlotinib (HY-50896) derivative, is an orally active, potent cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibitor. TD52 dihydrochloride mediates the apoptotic effect in triple-negative breast cancer (TNBC) cells via regulating the CIP2A/PP2A/p-Akt signalling pathway. TD52 dihydrochloride indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter. TD52 dihydrochloride has less p-EGFR inhibition and has potent anti-cancer activity . TD52 (dihydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-132913

Cyclopropenone probe 1		Alkynes
Cyclopropenone probe 1 can specifically and efficiently modify a triple-negative breast cancer driver, glutathione S-transferase pi-1 (GSTP1), by covalently binding at the catalytic active site. Cyclopropenone probe 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-157411

anti-TNBC agent-5		Alkynes
anti-TNBC agent-5 (compound 10C) is a triple-negative breast cancer (TNBC) inhibitor with good stability and pharmacokinetic properties. anti-TNBC agent-5 exhibits antiproliferative activity against a variety of cancer cells. anti-TNBC agent-5 can also effectively inhibit TNBC lung metastasis activity in the MDA-MB-231 xenograft model. anti-TNBC agent-5 can be used in cancer research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks